A cross-sectional survey of cannabis use by people with MS in Oregon and Southwest Washington

Evidence supports that cannabinoids reduce self-reported spasticity and neuropathic pain in people with MS (PwMS), and legal access to cannabis for medical and recreational use continues to rise. However, there are limited data regarding patterns of cannabis use and perceived benefits of cannabis among PwMS in the US. This study describes the prevalence of cannabis use, routes of administration, perceived benefit of cannabis for MS, and characteristics associated with cannabis use and perception of benefit among a population of PwMS living in two states where cannabis is legal for both medical and recreational use.

Cannabis use amongst patients with inflammatory bowel disease.

Authors: Simon Lal, Neeraj Prasad, Manijeh Ryan, Sabrena Tangri, Mark Silverberg, et al
European Journal of Gastroenterology & Hepatology, October 2011

BACKGROUND: Experimental evidence suggests the endogenous cannabinoid system may protect against colonic inflammation, leading to the possibility that activation of this system may have a therapeutic role in inflammatory bowel disease (IBD). Medicinal use of cannabis for chron…